US FDA’s Real-Time Oncology Review Program Is No Guarantee For Early Approval

 
• By Sue Sutter and Bridget Silverman
  
Early start
Under RTOR, FDA can get an early jump on reviewing a drug's efficacy and safety data. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Review Pathways

More from Pathways & Standards